Cimetidine Hydrochloride and Zevalin

• Generic Name: cimetidine
• Dosage Forms: n.a.
• Other Brand Names: Tagamet HB, Tagamet

Short-term treatment of active duodenal ulcer (endoscopically or radiographically confirmed).

Maintainence of healing and reduction in recurrence of duodenal ulcer.

Pathologic GI Hypersecretory Conditions

Long-term treatment of Zollinger-Ellison syndrome, multiple endocrine adenomas, systemic mastocytosis.

Gastric Ulcer

Short-term treatment of active benign gastric ulcer.

Gastroesophageal Reflux (GERD)

Short-term treatment of erosive esophagitis (endoscopically diagnosed) in patients with GERD.

Treatment of symptomatic GERD.

Self-medication as initial therapy to achieve acid suppression, control symptoms, and prevent complications of less severe symptomatic GERD.

Upper GI Bleeding

Prevention of upper GI bleeding resulting from stress-related mucosal damage (erosive esophagitis, stress ulcers) in critically ill patients.

Treatment of upper GI bleeding secondary to hepatic failure, esophagitis, duodenal or gastric ulcers when hemorrhage is not caused by major blood vessel erosion.

Heartburn (pyrosis), Acid Indigestion (hyperchlorhydria), or Sour Stomach

Short-term self-medication for relief of heartburn symptoms in adults and adolescents ≥12 years of age.

Short-term self-medication for prevention of heartburn symptoms associated with acid indigestion (hyperchlorhydria) and sour stomach brought on by ingestion of certain foods and beverages in adults and children ≥12 years of age.

• Generic Name: ibritumomab
• Dosage Forms: injection
• Other Brand Names: Y-90 Zevalin, In-111 Zevalin

Part of a specific therapeutic regimen (ibritumomab tiuxetan therapeutic regimen) for treatment of relapsed or refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL) (designated an orphan drug by FDA for this use). Safety and efficacy not evaluated in patients with ≥25% involvement of bone marrow by lymphoma and/or impaired bone marrow reserve (e.g., prior myeloablative therapies, prior external beam radiation to >25% of active marrow, neutrophil count <1500/mm3).

Ibritumomab tiuxetan therapeutic regimen also used for consolidation treatment of newly diagnosed follicular NHL in patients who have achieved partial or complete response to first-line induction chemotherapy. Safety and efficacy not evaluated in patients with ≥25% involvement of bone marrow by lymphoma and/or impaired bone marrow reserve (e.g., prior myeloablative therapies, prior external beam radiation to >25% of active marrow, platelet count <150,000/mm3).